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comorbidity (mean 0.41 +/- 0.30 vs. 0.72 +/- 0.25, p <
0.0001). In multivariate analyses, comorbidity remained
signiﬁcantly associated with HUI, even after controlling
for age, sex, case status, and deployment. CONCLU-
SIONS: Mental health comorbidity is common among
veteran populations. Its patterns resemble those found in
the general U.S. population. Mental health comorbidity
is strongly related to decreased quality of life among 
military veterans. Improvements in diagnosis and treat-
ment of mental health comorbidity may lead to enhanced
HRQoL.
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OBJECTIVES: Debate continues regarding the stability of
preferences across time and illness. The purpose therefore
was to determine if the experience of depressive disorder
changes patients’ risk attitudes and elasticity for time,
components of their standard gamble (SG) and time
trade-off (TTO) utilities. This study tests the explanatory
power of the Medical Care System Access Framework for
depression experience impact on patient preferences while
controlling for patient population characteristics.
METHODS: This study used two years of data from Part-
ners in Care, a group-level randomized controlled trial of
quality improvement programs for depression. For 1218
primary care patients with depression, we examined
single-item SG and TTO utilities at baseline and 24
months. Logistic regressions identiﬁed factors associated
with patients’ willingness to take risks and trade time 
and examined trends in utilities of individuals with and
without remission of depression as measured by the
Center for Epidemiologic Studies Depression screener and
the World Health Organization Composite International
Diagnostic Instrument. RESULTS: A dose-response gra-
dient indicating greater willingness to take risks or trade
time was found as depression increased. Patients who
continued to be depressed at 24 months were nearly 3
times more likely to be willing to assume risk or trade
time than patients whose depression remitted. Willingness
to assume risk or trade time increased in patients who
continued to be depressed at 24 months. However the SG
appeared to lack sensitivity in patients whose depression
remitted. Remission of depression was associated with a
decrease in willingness to trade time as expected and a
paradoxical increase in willingness to assume risk. CON-
CLUSIONS: Patients with depression appear to use a
single-item SG measure differently at baseline and 24
months. This could be due to changes in risk attitude
resulting from health experiences. Changes in values may
confound the use of single-item SG utilities as measures
of outcomes.
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OBJECTIVES: This analysis was designed to character-
ize longitudinal changes in quality of life in adults receiv-
ing publicly-funded treatment for substance use disorders.
METHODS: Clients were randomly sampled from 13
Massachusetts facilities providing publicly-funded deto-
xiﬁcation and outpatient drug treatment services. A total
of 206 adult clients completed an in-person baseline inter-
view and follow-up telephone interviews 1 year and 3
years later. Quality of life (QOL) was measured by the
SF-12 Physical Component Score (PCS) and Mental Com-
ponent Score (MCS). Latent growth modeling was used
to estimate the effects of ﬁve factors—age, gender, detox
status, managed care status, and drug treatment ser-
vices—on QOL trajectories over time. RESULTS: Seventy
percent of the clients were recruited from detoxiﬁcation
facilities, 52% were males, 52% were enrolled in Medic-
aid managed care plans, and 50% received drug treat-
ment services during the year prior to the last interview.
The growth models provided excellent ﬁts for both tra-
jectories. MCS scores increased from 31.0 at baseline to
38.9 at the time of the one year follow-up and remained
stable at year 3 (39.0). Clients recruited from detox
centers had signiﬁcantly lower MCS scores at baseline
and much higher slopes over time. The MCS trends were
essentially ﬂat for outpatients. The mean PCS score
increased from 43.6 to 46.1 after 1 year but then declined
back to 43.0 by the time of the 3-year follow-up. Base-
line physical functioning was negatively correlated with
client age and managed care status. PCS slopes declined
more rapidly for older clients than for younger respon-
dents. CONCLUSIONS: The results indicate that emo-
tional well-being for substance abusers improves after one
year and that this gain is maintained over the next two
years. Physical functioning rises and then falls. Managed
care and drug treatment during the intervening period
had little impact on QOL trajectories.
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients and -DS- in France. To highlight
a relation between DS and quality of life for patients suf-
fering from psoriasis. METHOD: Seven hundred ﬁfty
anonymous questionnaires (comprised 2 scales: the Pso-
riasis Disability Index [PDI] and the Center for Epidemi-
ologic Studies—Depression scale [CES-D] were sent, via
